Does the media prefer CGON or ROIV?

In the previous week, Roivant Sciences had 7 more articles in the media than CG Oncology. MarketBeat recorded 10 mentions for Roivant Sciences and 3 mentions for CG Oncology. Roivant Sciences' average media sentiment score of 0.98 beat CG Oncology's score of -1.00 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Roivant Sciences 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CGON or VTRS more profitable?

CG Oncology has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Viatris -2.04% 19.04% 7.62%

Does the media refer more to CGON or VTRS?

In the previous week, CG Oncology and CG Oncology both had 3 articles in the media. Viatris' average media sentiment score of 0.91 beat CG Oncology's score of -1.00 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Viatris 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MRNA or CGON more profitable?

CG Oncology has a net margin of 0.00% compared to Moderna's net margin of -143.55%. CG Oncology's return on equity of -23.33% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% CG Oncology N/A -23.33% -22.24%

Does the media prefer MRNA or CGON?

In the previous week, Moderna had 28 more articles in the media than CG Oncology. MarketBeat recorded 31 mentions for Moderna and 3 mentions for CG Oncology. Moderna's average media sentiment score of 0.44 beat CG Oncology's score of -1.00 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 13 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Which has stronger earnings & valuation, CGON or GMAB?

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,172.80 -$160.99M -$2.33 N/A Genmab A/S $3.72B 4.22 $963M $1.32 19.05

Is CGON or GMAB more profitable?

Genmab A/S has a net margin of 21.05% compared to CG Oncology's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Genmab A/S 21.05% 15.34% 8.94%

Does the media favor CGON or GMAB?

In the previous week, CG Oncology had 1 more articles in the media than Genmab A/S. MarketBeat recorded 3 mentions for CG Oncology and 2 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.35 beat CG Oncology's score of -1.00 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ASND or CGON?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than CG Oncology. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 3 mentions for CG Oncology. Ascendis Pharma A/S's average media sentiment score of 1.16 beat CG Oncology's score of -1.00 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

CG Oncology (CGON) Competitors

$53.72 -2.37 (-4.23%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$53.70 -0.02 (-0.04%)

As of 06/5/2026 05:22 PM Eastern

Compare

CGON vs. ROIV, VTRS, MRNA, GMAB, and ASND

Should you buy CG Oncology stock or one of its competitors? MarketBeat compares CG Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CG Oncology include Roivant Sciences (ROIV), Viatris (VTRS), Moderna (MRNA), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

How does CG Oncology compare to Roivant Sciences?

CG Oncology (NASDAQ:CGON) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

CG Oncology currently has a consensus price target of $81.73, suggesting a potential upside of 52.14%. Roivant Sciences has a consensus price target of $33.59, suggesting a potential upside of 17.53%. Given CG Oncology's higher probable upside, research analysts clearly believe CG Oncology is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

CG Oncology has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

In the previous week, Roivant Sciences had 7 more articles in the media than CG Oncology. MarketBeat recorded 10 mentions for Roivant Sciences and 3 mentions for CG Oncology. Roivant Sciences' average media sentiment score of 0.98 beat CG Oncology's score of -1.00 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Roivant Sciences	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has higher earnings, but lower revenue than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,172.80	-$160.99M	-$2.33	N/A
Roivant Sciences	$8.26M	2,488.71	-$299.77M	-$0.60	N/A

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CG Oncology has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Summary

Roivant Sciences beats CG Oncology on 11 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Viatris?

CG Oncology (NASDAQ:CGON) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

CG Oncology has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Viatris	-2.04%	19.04%	7.62%

In the previous week, CG Oncology and CG Oncology both had 3 articles in the media. Viatris' average media sentiment score of 0.91 beat CG Oncology's score of -1.00 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

CG Oncology currently has a consensus price target of $81.73, indicating a potential upside of 52.14%. Viatris has a consensus price target of $17.50, indicating a potential upside of 10.20%. Given CG Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe CG Oncology is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CG Oncology has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,172.80	-$160.99M	-$2.33	N/A
Viatris	$14.30B	1.29	-$3.51B	-$0.26	N/A

Summary

CG Oncology beats Viatris on 8 of the 15 factors compared between the two stocks.

How does CG Oncology compare to Moderna?

Moderna (NASDAQ:MRNA) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

CG Oncology has a net margin of 0.00% compared to Moderna's net margin of -143.55%. CG Oncology's return on equity of -23.33% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
CG Oncology	N/A	-23.33%	-22.24%

75.3% of Moderna shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Moderna had 28 more articles in the media than CG Oncology. MarketBeat recorded 31 mentions for Moderna and 3 mentions for CG Oncology. Moderna's average media sentiment score of 0.44 beat CG Oncology's score of -1.00 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	13 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

CG Oncology has lower revenue, but higher earnings than Moderna. CG Oncology is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.68	-$2.82B	-$8.15	N/A
CG Oncology	$4.04M	1,172.80	-$160.99M	-$2.33	N/A

Moderna presently has a consensus target price of $35.73, indicating a potential downside of 24.68%. CG Oncology has a consensus target price of $81.73, indicating a potential upside of 52.14%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts plainly believe CG Oncology is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Summary

Moderna and CG Oncology tied by winning 8 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Genmab A/S?

CG Oncology (NASDAQ:CGON) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

CG Oncology presently has a consensus price target of $81.73, indicating a potential upside of 52.14%. Genmab A/S has a consensus price target of $37.93, indicating a potential upside of 50.81%. Given CG Oncology's higher possible upside, research analysts clearly believe CG Oncology is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Genmab A/S has a net margin of 21.05% compared to CG Oncology's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Genmab A/S	21.05%	15.34%	8.94%

In the previous week, CG Oncology had 1 more articles in the media than Genmab A/S. MarketBeat recorded 3 mentions for CG Oncology and 2 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.35 beat CG Oncology's score of -1.00 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,172.80	-$160.99M	-$2.33	N/A
Genmab A/S	$3.72B	4.22	$963M	$1.32	19.05

CG Oncology has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Summary

Genmab A/S beats CG Oncology on 11 of the 17 factors compared between the two stocks.

How does CG Oncology compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Ascendis Pharma A/S currently has a consensus price target of $295.39, suggesting a potential upside of 40.36%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 52.14%. Given CG Oncology's higher probable upside, analysts clearly believe CG Oncology is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

26.6% of CG Oncology shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CG Oncology has lower revenue, but higher earnings than Ascendis Pharma A/S. CG Oncology is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	16.12	-$258M	$8.67	24.27
CG Oncology	$4.04M	1,172.80	-$160.99M	-$2.33	N/A

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than CG Oncology. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 3 mentions for CG Oncology. Ascendis Pharma A/S's average media sentiment score of 1.16 beat CG Oncology's score of -1.00 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Ascendis Pharma A/S has a net margin of 57.87% compared to CG Oncology's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
CG Oncology	N/A	-23.33%	-22.24%

Summary

Ascendis Pharma A/S beats CG Oncology on 13 of the 17 factors compared between the two stocks.

Get CG Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGON vs. The Competition

Export

Metric	CG Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.95B	$3.35B	$6.47B	$12.42B
Dividend Yield	N/A	2.33%	2.68%	5.34%
P/E Ratio	-23.06	18.85	23.79	23.63
Price / Sales	1,172.80	307.82	543.15	124.82
Price / Cash	N/A	114.83	42.35	57.17
Price / Book	5.76	6.51	9.73	6.35
Net Income	-$160.99M	$24.15M	$3.57B	$337.59M
7 Day Performance	-13.76%	-6.96%	-1.25%	-2.51%
1 Month Performance	-21.01%	-4.27%	0.83%	-0.68%
1 Year Performance	99.63%	36.81%	24.11%	25.37%

CG Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGON CG Oncology	2.7728 of 5 stars	$53.72 -4.2%	$81.73 +52.1%	+101.7%	$4.95B	$4.04M	N/A	61
ROIV Roivant Sciences	3.1202 of 5 stars	$29.67 -1.0%	$33.59 +13.2%	+155.2%	$21.23B	$8.26M	N/A	860	News Coverage Positive News
VTRS Viatris	3.4765 of 5 stars	$16.26 -2.3%	$16.43 +1.0%	+87.7%	$18.94B	$14.30B	N/A	30,000
MRNA Moderna	1.5365 of 5 stars	$47.03 +0.3%	$35.73 -24.0%	+81.6%	$18.66B	$1.94B	N/A	4,700
GMAB Genmab A/S	4.0116 of 5 stars	$26.89 +0.1%	$39.07 +45.3%	+15.3%	$16.77B	$3.72B	20.37	3,029	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGON) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CG Oncology (CGON) Competitors

CGON vs. ROIV, VTRS, MRNA, GMAB, and ASND

How does CG Oncology compare to Roivant Sciences?

Summary

How does CG Oncology compare to Viatris?

Summary

How does CG Oncology compare to Moderna?

Summary

How does CG Oncology compare to Genmab A/S?

Summary

How does CG Oncology compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CG Oncology (CGON) Competitors

CGON vs. ROIV, VTRS, MRNA, GMAB, and ASND

How does CG Oncology compare to Roivant Sciences?

Do analysts prefer CGON or ROIV?

Is CGON or ROIV more profitable?

Does the media prefer CGON or ROIV?

Which has preferable valuation & earnings, CGON or ROIV?

Do insiders & institutionals hold more shares of CGON or ROIV?

Which has more volatility and risk, CGON or ROIV?

Summary

How does CG Oncology compare to Viatris?

Is CGON or VTRS more profitable?

Does the media refer more to CGON or VTRS?

Which has more volatility and risk, CGON or VTRS?

Do analysts rate CGON or VTRS?

Do institutionals & insiders believe in CGON or VTRS?

Which has stronger earnings and valuation, CGON or VTRS?

Summary

How does CG Oncology compare to Moderna?

Is MRNA or CGON more profitable?

Do insiders & institutionals have more ownership in MRNA or CGON?

Does the media prefer MRNA or CGON?

Which has higher earnings and valuation, MRNA or CGON?

Do analysts prefer MRNA or CGON?

Which has more volatility and risk, MRNA or CGON?

Summary

How does CG Oncology compare to Genmab A/S?

Do analysts recommend CGON or GMAB?

Is CGON or GMAB more profitable?

Does the media favor CGON or GMAB?

Do insiders and institutionals believe in CGON or GMAB?

Which has stronger earnings & valuation, CGON or GMAB?

Which has more risk and volatility, CGON or GMAB?

Summary

How does CG Oncology compare to Ascendis Pharma A/S?

Which has more volatility & risk, ASND or CGON?

Do analysts rate ASND or CGON?

Do institutionals & insiders hold more shares of ASND or CGON?

Which has better earnings & valuation, ASND or CGON?

Does the media prefer ASND or CGON?

Is ASND or CGON more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools